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Cerebral aspergillosis is a rare pathology of poor prognosis in spite of the use of adapted antifungal treatments. This infection of
the central nervous system is generally the complication of an invasive aspergillosis with hematogenic scattering from pulmonary
focal spots. It can arise in immunocompetent patients treated with prolonged corticotherapy or chemoradiotherapy for cancer. A
case of lethal cerebral aspergillosis in a patient with an inﬁltrative glioma treated with corticotherapy and radiotherapy is reported.
Clinicopathological aspects and therapeutic approach are described.
1.Introduction
Infections of the central nervous system (CNS) are major
complications of antineoplastic treatments, mainly because
of drugs that weaken the immune system, in particular cor-
ticotherapy and chemotherapy. During invasive aspergillo-
sis, the cerebral location is a frequent complication. The
prognosis is then unfavourable, with a mortality rate of
about 86% [1–3]. It is mostly a postmortem diagnosis.
The presentation of a cerebral aspergillosis is polymorphic:
meningitis, meningoencephalitis, granuloma, brain abscess,
and vasculitis. It can mimic cerebral tuberculosis, pyogenic
abscess, or brain tumour. Symptoms are nonspeciﬁc; the
patient can be apyretic [4–6]. Aspergillosis is an infection
diﬃcult to treat, especially in immunosuppressed patients.
The fungus reaches the CNS by hematogenic scattering from
peripheral focal spots; the portal of entry is mostly the lung
[6]. A cerebral involvement due to an infected paranasal
sinus is also possible. Occurrence of a cerebral aspergillosis
in patients with an inﬁltrative glioma does not seem rare in
view of our listed cases (Table 1). We choose to report here
one of these clinicopathological histories (case A).
2. Case Presentation
A 66-year-old male, smoker, with diﬀuse atheromatosis, pre-
sented with intracranial hypertension, gradually increasing
in gravity. A left occipital tumor was biopsied, leading to
the discovery of a cerebral grade III-IV glioma (WHO 2007
classiﬁcation) near the left ventricular atrium, not operable
because of its critical location close to functional areas.
Radiotherapy was decided to deliver 60Gy in the tumor
volume associated with corticotherapy. The treatment was
well tolerated. Temozolomide chemotherapy was secondarily
planned.
Mechanical left coxalgia and pygalgia appeared few
weeks after the treatment. MRI was suggestive of aseptic
osteonecrosis of the left femoral head of cortisonic ori-
gin. Increasing pain was concomitant with oedema of the2 Case Reports in Medicine
Table 1: List of cases diagnosed in our hospital between September 1997 and August 2008.
Case Brain tumor type Treatment type
Pulmonary
aspergillosis
occurrence
Cerebral
aspergillosis
occurrence
A Grade III-IV glioma Corticotherapy and radiotherapy Yes Yes
B Glioblastoma
Corticotherapy,
polychemotherapy, and
radiotherapy
Yes Yes
C Grade III glioma (astrocytoma) Corticotherapy Yes Yes
D Grade III glioma (astrocytoma) Corticotherapy Yes Yes
Figure 1: T1-weighted contrast-enhanced coronal MRI. Hypoint-
ense nodular lesion in the right capsulothalamic area, with periph-
eral annular enhancement. Small cortical-subcortical ipsilateral
satellite lesion with annular enhancement and perilesional edema.
left lower limb. Ultrasound revealed a left coxofemoral
intra-articular eﬀusion and eliminated venous thrombosis.
A feverish syndrome appeared then, but bacteriological
samples were negative. However, a neurological syndrome
appeared, consisting of apathy, drowsiness, mnesic troubles,
likely secondary to the cerebral radiotherapy and morphinic
painkillers. The patient was transferred to the infectious
disease unit, where a left hemiparesis was noticed. The
brain CT scan showed multifocal hypodensities compatible
with cerebral abscesses. The lumbar puncture did not show
elevated cell count; the bacteriological examination was
negative.Aprobabilisticbiantibiotictherapywasestablished,
in association with an intravenous antiherpetic treatment.
Consciousness quickly degraded. A cerebral MRI was under-
taken, ﬁnding images suggestive of multifocal abscesses
(Figure 1).
The patient was transferred to the intensive care unit for
septic shock. MRI of the left lower limb showed necrotizing
fasciitis with myonecrosis. Multiple lung lesions suggestive
of septic emboli were noticed on the thoracic CT scan. A
surgicalwoundcarewasundertakenforanextensivecellulitis
of the left lower limb.
During theinfectiousinvestigation, anaspergillarantige-
naemia returned positive, conﬁrmed on two other samples,
suggestive of invasive aspergillosis. Mycological and para-
s i t o l o g i c a le x a m i n a t i o n sw e r en e g a t i v ef o rc r y p t o c o c c o s i s
and toxoplasmosis, in particular in the cerebrospinal ﬂuid
(CSF). The sample of necrotizing fasciitis was positive for
polybacterial intestinal ﬂora, compatible with anoperineal
portal of entry. A polyantibiotic therapy was established,
in association with the intravenous Voriconazole, in the
hypothesis of aspergillar cerebral abscesses.
Th ec o u r s eo fs e pti cs h oc kw a su n f a v o u ra b l e ;as y n d r o m e
of multivisceral failure developed. The follow-up cerebral
CT scan found multiple round opacities with mass eﬀect,
suggestive of abscesses with midline deviation. The gravity
of the situationbrought about canceling the cerebral micro-
biological biopsy. Death followed cardiocirculatory collapse.
In brief; this patient with cerebral high-grade glioma,
under long-term corticosteroids, underwent a septic shock
secondary to an extensive cellulitis of the left lower limb. A
neurological syndrome with left hemiplegia and conscious-
ness degradation was related to aspergillar cerebral abscesses
with mass eﬀect.
An autopsy was undertaken:
(i) on the infectious side, there were abscesses of both
superior pulmonary lobes. The microscopic exam-
ination brought to light aspergillar abscesses with
branched out Grocott-positive ﬁlaments, within
necrotic tissue. An aspect of fasciitis of the left lower
limb was also found. The macroscopic examination
of the brain revealed an abscessed right frontal
callosal mass (Figure 2) and satellite microabscesses
separated from this main focal spot, associated with
bilateral uncal herniation. During microscopy, we
noticed zones of necrosis rich in altered polynu-
clear cells (Figure 3). PAS (periodic acid Schiﬀ)
and Grocott-positive mycelial strands were brought
to light, often surrounded with polynuclear cells.
Within these abscessed focal spots of mycelial ori-
gin, the branched-out aspect of ﬁlaments and their
morphology suggested mycosis due to Aspergillus
fumigates,
(ii) on the carcinological side, we noticed a left hematic
and necrotic parietooccipital lesion, compatible with
an intratumoral hematoma. During microscopy, it
appeared that the necrotic center was surrounded
with an important glial reaction, within which
neoangiogenesis and cells with large nuclei were
observed. Macrophages loaded with hemosiderin
were also observed,Case Reports in Medicine 3
Figure 2: Autopsic brain coronal section. Right thalamus and coro-
na radiata abscessed hemorrhagic infarcts.
Figure 3: Corresponding histopathological section, stained with
hematoxylin and eosin, showing hemorrhagic necrosis rich in
altered polynuclear cells.
(iii) besides, a recent infarct was located in the lateral
subdivision of the thalami, doubtless secondary to
compressionoftheposteriorcerebralarteriesbecause
of bilateral uncal herniation.
In brief; multiple pulmonary and cerebral aspergillar ab-
scesses coexisted with a necroticohemorrhagic brain lesion,
which was surrounded with neoangiogenesis, suggesting a
tumor lesion reshaped by radiotherapy.
Note that this clinicopathological history matches with
our other cases of listed gliomas, treated in a constant way by
corticotherapy with an antiedematous aim (Table 1).
3. Discussion
Corticosteroids act on various stages of the immune re-
sponse: they inhibit the presentation of antigens on the
surface of monocytes/macrophages dependent on HLA class
II histocompatibility antigens, the T-lymphocytes prolif-
eration dependent on interleukin-1 (IL-1) and on IL-2,
and the cytotoxicity (T and NK) that is dependent on
interferon-gamma and on IL-2. Any prolonged cortisonic
treatmentofmorethan15daysdecreasesimmunefunctions,
especially those carried out by T cells, while levels of
antibodies synthesized by B-lymphocytes are little modi-
ﬁed. Corticosteroids inhibit the migration of polynuclear
neutrophils towards inﬂammatory sites and limit their
apoptosis, explaining the polynucleosis classically observed
under corticosteroid treatment [7]. We guess that, in
most infectious diseases, a prolonged corticotherapy, by
decreasingtwofundamentalmeansofdefense,inﬂammation
and immunity, can have catastrophic consequences. It is
possible that the presence of a brain tumor is a cofactor
favoring the development of cerebral aspergillosis, especially
in the context of systemic immunosuppression. The possible
local immunological disorders, associated with a greater
permeability of the blood-brain barrier, could facilitate a
fungal cerebral settlement in case of septicemia from a
pulmonary focal spot.
Aspergillus fumigatus is the most common variety of
Aspergillus. It is a commensal of the respiratory tract, which
is the portal of entry. Cerebral aspergillosis is caused more
frequently by Aspergillus fumigatus, in context of invasive
aspergillosis with hematogenic scattering from pulmonary
focal spots [6, 8]. In 90% of cases, the primary infectious
site is the lung. The cerebral involvement aﬀects 20%
of patients with invasive aspergillosis [9]. Treatment with
immunosuppressive drugs, prolonged corticotherapy, and
radiochemotherapyinpatientsalreadyweakenedbyaninter-
current pathology increases the probability of an aspergillar
infection [2, 10, 11]. The diagnosis of cerebral aspergillosis
is diﬃcult because the inaugural symptoms are mostly not
speciﬁc[3]:headaches,paralysisofcranialorsomaticnerves,
paresthesias, mental confusion, and/or epileptic seizures.
Moreover,hemoculturesandmicrobiologicalexaminationof
theCSFarefrequentlynegative[12].Diagnosticcertaintycan
be obtained by an aspiration biopsy of one of the abscesses
after stereotactic location. Unfortunately, this gesture is
not always practicable due to comorbidities such as severe
underlying pathology or frequent pancytopenia and due to
critical location of abscesses for example at the level of basal
ganglia, with an important risk of severe complications.
In this context we have indirect methods of diagnosis, the
principle of which ensues from the very frequent scattering
of aspergillosis in sites other than the CNS [13].
The presence of uni- or multifocal abscesses associated
with vascular invasion leading to thrombosis is a char-
acteristic feature of aspergillosis during neuropathologic
examination. Aspergillus tends to invade arteries and veins
because of its angiotropism, leading to necrotizing vasculitis,
secondary thrombosis, and hemorrhage. There is often an
infectious extension by contiguity [14]. The initially sterile4 Case Reports in Medicine
infarcts can evolve into septic infarcts with formation of
abscesses [15].
Aspergillosis generates typical wide septate ﬁlaments
with dichotomous branching, associated with signs of vas-
cular invasion, granulomatous formation, and giant cell
reaction. Extension of fungal invasion in the neighbouring
neuronal tissues and in blood vessels provokes hemorrhage,
thrombosis, infarcts, necrosis, meningitis, and ventriculitis.
This extension is at the origin of the varied clinicopatholog-
ical aspects of cerebral aspergillosis. The neuropathological
observations also depend on the depth of immunosup-
pression. In case of extreme immunosuppression like in
bone marrow transplant or prolonged severe neutropenia,
numerousaspergillarstrandsarefoundassociatedwithbadly
bounded inﬂammation, constituted of some mononuclear
and polynuclear cells. In case of less severe immunosup-
pression, inﬂammation is frank with frequent formation of
granulomas constituted of lymphocytes, plasmocytes, and
rare mycelial strands. Necrotic damage is frequent, whatever
is the depth of immunodeﬁciency, conﬁrming the vascular
tropism of the pathogen.
Invasion of thalamoperforant and lenticulostriate arter-
ies, responsible for thalamic and basal ganglia infarcts,
suggests the diagnosis of cerebral aspergillosis, especially
when the clinical context is evocative [14].
The most eﬀective treatment of cerebral aspergillosis
is medical and surgical. For a long period of time, the
antifungal medication of reference was Amphotericin B, free
or liposomal. Now, antifungal ﬁrst-line treatment of invasive
aspergillosis is Voriconazole, whose eﬃciency and tolerance
are superior to Amphotericin B; its good intracerebral
distribution justiﬁes its ﬁrst use in cerebral aspergillosis [16,
17]. The best results are obtained by associating antifungal
medication with surgery of cerebral locations [18]. However,
immunosuppression and deep critical location of these
brain lesions make surgery rarely possible. The eﬃciency of
intracavitary or intrathecal injection of Amphotericin B is
not proved; it is exposed to severe iatrogenic complications
such as meningitis, arachnoiditis, myelitis, or paralysis of
cranial nerves [19].
Cerebral aspergillosis is of unfavourable prognosis. The
mortalityrate,whichoscillatesbetween80and90%,iscorre-
lated with the time left before treatment starts. Aspergillosis
abscesses in patients with progressive cancer are generally
lethal [20]. Factors that favor the therapeutic eﬃcacy are
(i) a unifocal and isolated character of the lesion, with-
out scattering,
(ii) absence of neurological signs,
(iii) early diagnosis,
(iv) preventive administration of an antifungal treatment
in patients at risk for aspergillosis.
4. Conclusion
It would be advisable to keep in mind the risk of a
fungal infection in any patient with a malignant tumor,
including a cerebral tumor. Cerebral aspergillosis is a serious
disease. This diagnosis should be suspected early to avoid
a deleterious therapeutic delay, in particular in a context
of immunosuppression, in the presence of pulmonary
aspergillosis and typical location of lesions at the level of
thalami and basal ganglia, particularly if there are multiple
hemorrhagic infarcts on imaging.
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